STOCKROUTINES

Pfizer Inc.

Last Updated
Share Price
$49.03
Market Cap
$276.91B
Dividend Yield
N/A
EPS
$3.85
P/E
12.72

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

0%
Income
  • Revenue $81.29B
  • Gross Profit $50.47B
  • Net Income $21.98B
  • Gross Margin 62.08%
  • Net Margin 27.04%
Cash Flow
  • Free Cash Flow (FCF) $29.87B
  • Free Cash Flow To Equity (FCFE) $27.77B
  • Dividends Paid $-8.73B
  • Debt Repayment $-2.1B
  • Net Stock Repurchased $0
Balance Sheet
  • Shareholder Equity $77.2B
  • Debt To Equity (D/E) 134.73%
  • Book Value $77.46B
  • Book Value Per Share (BVPS) $0
  • Return On Invested Capital (ROIC) 20.67%
The financial metrics for Pfizer Inc. presented below are for the financial year 2021.
P/E 15.05 Price To Earnings Ratio
P/S 4.07 Price To Sales Ratio
P/B 4.27 Price To Book Ratio
P/CF 10.15 Price To Operating Cash Flow Ratio
P/FCF 11.07 Price To Free Cash Flow Ratio
P/FCFE 11.91 Price To Levered Free Cash Flow Ratio
P/EBT 13.6 Price To Pre-Tax Income
PEG 0.18 Trailing Price/Earnings To Growth Ratio
EV/Sales 4.5 Enterprise Value To Sales Ratio
EBIT/EV 0.07 EBIT To Enterprise Value Ratio
EV/EBITDA 12.07 Enterprise Value to EBITDA Ratio
D/E 1.35 Debt To Equity Ratio
ROE 31.3% Return On Equity
ROIC 20.67% Return On Invested Capital
DPR 39.72% Dividend Payout Ratio
Current Ratio 1.4 Current Liquidity Ratio
EPS Growth 81.57% Earnings Per Share Growth Rate
Graham Number $34.93 Benjamin Graham's Number
Piotroski Score N/A Piotroski F-Score
Beta N/A Beta Coefficient Value
    2021 2020 2019 2018 2017
Revenue $81.29B$41.91B$51.75B$53.65B$52.55B
Cost of Revenue $30.82B$8.69B$10.22B$11.25B$11.24B
Gross Profit $50.47B$33.22B$41.53B$42.4B$41.31B
Gross Profit Margin 62.08%79.26%80.25%79.03%78.61%
Operating Expenses $30.23B$24.46B$27.61B$27.35B$27.2B
Research & Development Expenses (R&D) $13.83B$9.4B$8.65B$8.01B$7.66B
Selling, General & Administrative Expenses (SG&A) $12.7B$11.62B$14.35B$14.46B$14.78B
Other Expenses $3.7B$3.44B$4.61B$4.89B$4.76B
Net Income $21.98B$9.62B$16.27B$11.15B$21.31B
Net Profit Margin 27.04%22.95%31.45%20.79%40.55%
Operating Income $20.23B$8.76B$13.92B$15.04B$14.11B
Other Income & Expenses (Net) $4.08B$-1.26B$3.76B$-3.16B$-1.8B
Depreciation & Amortization $5.19B$4.78B$6.01B$6.38B$6.27B
Interest Income $36M$73M$226M$333M$391M
Interest Expense $1.29B$1.45B$1.57B$1.32B$1.27B
Income Tax Expense $1.85B$477M$1.38B$706M$-9.05B
Effective Tax Rate 7.62%6.36%7.83%5.94%-73.54%
EBITDA $30.31B$16.32B$25.24B$19.56B$19.8B
EBIT $25.12B$11.54B$19.23B$13.18B$13.53B
EBT N/AN/AN/AN/AN/A
Shares Outstanding 5.6B5.55B5.57B5.87B5.97B
Diluted Shares Outstanding 5.71B5.63B5.67B5.98B6.06B
EPS $3.92$1.73$2.92$1.9$3.57
Diluted EPS $3.85$1.71$2.87$1.87$3.52
    2021 2020 2019 2018 2017
Operating Cash Flow $32.58B$14.4B$12.59B$15.83B$16.47B
Net Income $21.98B$9.62B$16.27B$11.15B$21.31B
Depreciation & Amortization $5.19B$4.78B$6.01B$6.38B$6.27B
Deferred Income Tax $-4.29B$-1.47B$614M$-2.21B$-2.41B
Stock-Based Compensation $1.18B$756M$718M$949M$840M
Change In Working Capital $12.8B$13.65B$-22.57B$7.35B$2.88B
Other Non-Cash Items $-4.28B$-12.93B$11.54B$-7.81B$-12.42B
Cash From Investing $-22.55B$-4.27B$-3.94B$4.53B$-4.74B
Purchases Of Investments $-47.61B$-14.4B$-7.04B$-13.47B$-18.13B
Sales / Maturities of Investments $28.1B$12.73B$16.34B$19.91B$15.96B
Property, Plant & Equipment Investments $-2.71B$-2.25B$-2.18B$-2.04B$-1.96B
Net Acquisitions $0$0$-10.86B$0$-1B
Other Investing Activites $-318M$-347M$-212M$133M$389M
Cash From Financing $-9.82B$-9.65B$-8.48B$-20.44B$-13.04B
Debt Repayment $-2.1B$-30.33B$-12.63B$-9.62B$-14.74B
Dividend Payments $-8.73B$-8.44B$-8.04B$-7.98B$-7.66B
Payout Ratio 39.72%87.77%49.43%71.53%35.94%
Net Common Stock Repurchased $0$0$8.87B$12.2B$5B
Common Stock Repurchased $0$0$-8.87B$-12.2B$-5B
Common Stock Issued $0$0$8.87B$12.2B$5B
Other Financing Activites $1.01B$29.12B$21.06B$9.36B$14.37B
Accounts Receivables $-3.81B$-1.25B$-742M$-644M$259M
Accounts Payables $1.24B$353M$-564M$431M$46M
Inventory $-1.13B$-736M$-1.05B$-717M$-357M
Other Working Capital $-1.17B$9.15B$-4.5B$18.07B$10.71B
Capital Expenditure (CAPEX) $-2.71B$-2.79B$-2.59B$-2.2B$-2.22B
Effect Of Foreign Exchange On Cash $-59M$-8M$-32M$-116M$53M
Net Change In Cash $158M$475M$125M$-206M$-1.25B
Free Cash Flow (FCF) $29.87B$11.61B$9.99B$13.63B$14.25B
Free Cash Flow To Equity (FCFE) $27.77B$-18.72B$-2.64B$4.01B$-490M
    2021 2020 2019 2018 2017
Total Assets $181.48B$154.23B$167.49B$159.42B$171.79B
Total Current Assets $59.69B$35.07B$32.8B$49.93B$41.14B
Cash & Short-Term Investments $31.07B$12.22B$9.83B$18.83B$19.99B
Cash & Cash Equivalents $1.94B$1.78B$1.3B$1.14B$1.34B
Short-Term Investments $29.13B$10.44B$8.53B$17.69B$18.65B
Net Receivables $15.74B$11.19B$12.07B$11.4B$11.27B
Inventory $9.06B$8.05B$8.28B$7.51B$7.58B
Other Current Assets $3.82B$3.61B$2.62B$12.19B$2.3B
Total Non-Current Assets $121.78B$119.16B$134.69B$109.5B$130.65B
Property, Plant & Equipment (PP&E) $14.88B$13.9B$13.97B$13.38B$13.87B
Goodwill & Intangible Assets $74.35B$78.05B$94.02B$88.62B$104.69B
Goodwill $49.21B$49.58B$58.65B$53.41B$55.95B
Intangible Assets $25.15B$28.47B$35.37B$35.21B$48.74B
Long-Term Investments $21.53B$20.26B$20.15B$2.77B$7.01B
Other Non-Current Assets $7.68B$4.57B$4.45B$2.8B$3.23B
Other Assets $243.56B$0$0$0$0
Total Liabilities $104.01B$90.76B$104.04B$95.66B$100.14B
Total Current Liabilities $42.67B$25.92B$37.3B$31.86B$30.43B
Accounts Payables $5.58B$4.31B$4.22B$4.67B$4.66B
Short-Term Debt $2.24B$2.7B$16.19B$8.84B$9.94B
Deferred Revenue $3.07B$0$0$0$0
Other Current Liabilities $31.79B$18.91B$16.89B$18.35B$15.83B
Total Non-Current Liabilities $61.34B$64.84B$66.74B$63.81B$69.71B
Long-Term Debt $34.76B$35.57B$35.95B$32.43B$32.67B
Other Non-Current Liabilities $26.24B$25.2B$25.2B$27.68B$33.15B
Total Debt $37B$38.27B$52.15B$41.27B$42.61B
Total Shareholder Equity $77.2B$63.24B$63.14B$63.41B$71.31B
Common Stock $473M$470M$468M$467M$464M
Retained Earnings $103.39B$96.77B$97.67B$89.55B$85.29B
Accumulated Other Comprehensive Income Loss (AOCL) $-5.9B$-14.81B$-11.64B$-11.28B$-9.32B
Other Shareholder Equity $-20.77B$-19.19B$-23.37B$-15.36B$-5.15B
Total Investments $50.65B$30.7B$28.67B$20.46B$25.66B
Net Debt $35.05B$36.49B$50.84B$40.13B$41.26B
Book Value $77.46B$63.47B$63.45B$63.76B$71.65B

Discounted Cash Flow

Use the Discounted Cash Flow (DCF) tool to estimate the intrinsic value of Pfizer Inc. stock.

Assumptions
Forecast Period
Required Return
  Low Mid High
Revenue Growth
FCFE Margin
Perpetual Growth
Terminal P/FCFE
Assumptions

The number of assumptions to make for each forecast.

Forecast Period

The number of years to forecast future cash flows. These future cash flows are used to determine the intrinsic present value for the stock.

It is generally recommended to select a longer period for more established companies with stable financial histories.

Forecast Period

The compounding annual rate of return required, according to your investment objectives. This is used to discount back future cash flows.

Revenue Growth

Estimate the annual compounding revenue growth rate. You can use the historical compounding annual growth rates provided below as a guide.

  • 1 Year 66.07%
  • 3 Years 10.36%
  • 5 Years 6.26%
  • 10 Years 6.26%
Levered Free Cash Flow Margin

Estimate levered free cash flow (FCFE) as a percentage of revenue. You can use the historical margins provided below as a guide.

  • 1 Year 34.16%
  • 3 Years -5.2%
  • 5 Years -1.81%
  • 10 Years -1.81%
Perpetual Growth Rate

Estimate the compounding annual growth rate at which revenues will grow in perpetuity after the forecast period. This is the first method used to calculate the terminal value.

Values of between 2% and 5% are generally recommended.

Price To Levered Free Cash Flow

Estimate the price to levered free cash flow (P/FCFE) for the stock after the forecast period. This is the second method used to calculate the terminal value.

This method for calculating the terminal value can be preferred for shorter forecast periods. You can use the historical rations provided below as a guide.

  • 1 Year 11.91
  • 3 Years -25.82
  • 5 Years -87.61
  • 10 Years -87.61
Chief Executive Officer (CEO) Dr. Albert Bourla
Full-Time Employees 79K
Industry Drug Manufacturers—General
Sector Healthcare
Country US
Website https://www.pfizer.com

Copyright © 2022 STOCKROUTINES